Alnylam Shares Plunge as a Drug Candidate Is Discontinued

Alnylam Pharmaceuticals ’ shares dropped after discontinued development of its rare-disease treatment revusiran following unfavorable clinical trial data.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news